New Treatments for AML Remain Elusive, But Researchers Are UndeterredLauren M. Green
Meanwhile, there are still a large number of patients without sensitive driven mutations who are not available for TKI treatments [36]. Therefore, it is particularly important to find new therapeutic targets for NSCLC patients with different driven mutations or with TKI resistance. In recent years,...
These AML survival pathways are involved in drug resistance, evasion of the immune system, reprogramming metabolism, and impairing differentiation. In addition, based on the reports of enhanced clinical efficiencies when combining drugs or treatments, deeper investigation into possible pathways, which can...
“With all of the tools available to us today, as clinicians, we are really relying on cross-trial comparisons and safety cross-trial comparisons to guide our treatments. So, if we come back to the clinical dilemma that we all face today— what do we do with that [patient ...
The goal of this activity is to improve the knowledge and competence in the rationale for and use of CD47 targeting agents in the treatment of MDS and AML. Target Audience This global educational program is intended for hematologists, medical oncologists, and other healthcare professionals who tr...
Unfortunately, available Chokα inhibitors also have toxic side-effect and are not approved for use in patients. Hopefully, this research might encourage screening for safe drugs interfering with these pathways and contribute the development of new treatments for AITL....
Drugs targeting LSCs including natural products, synthetic drugs, antibodies or adoptive immune cells have shown beneficial effects in preclinical and clinical researches, especially when combined with existing AML treatments. Due to the complex biological characteristics of LSCs and AML cells, treatment ...
trial (NCT05144009)] in DLBCL with loncastuximab plus rituximab [in] elderly [patients]. I find that one to be particularly exciting because elderly patients with DLBCL are not well served by current standards of care, if there is such a thing. We need better ...
These technologies will help reduce the time to market for potential new treatments by accelerating the approval process and will streamline the user experience during patient enrollment. Changing how AML is treated Recognizing the urgent need to do better for ...
although there has been progress along those lines. The other is treatments or approaches that will result in a tangible improvement in overall survival. With some of these drugs, there have been data to suggest at least a modest improvement in overall survival, but we would like to see with...